Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat + Cerezyme in Adult Gaucher Disease Type 3 With Venglustat Monotherapy Extension
2023-508646-18-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of venglustat in Gaucher disease type 3 and Gaucher disease type 1 (GD1) (2 arms), sponsored by Sanofi. Primary endpoints: Treatment-emergent adverse events and CSF lyso-glucosylceramide and glucosylceramide levels. Started Sep 2017; status: completed.
02
Drugs
venglustat
03
Conditions
Gaucher disease type 3Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2023-508646-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508646-18-00.